Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

CAR-Multicenter Analysis (CAR-MA): studio retrospettivo per caratterizzare gli esiti delle cellule CAR-T e le tossicità correlate nei bambini e nei giovani adulti con B-ALL

23 ottobre 2026 aggiornato da: National Cancer Institute (NCI)

Study Description:

This retrospective protocol focuses on characterizing clinical outcomes and toxicities following CAR T-cell therapy.

Objectives:

Primary

To evaluate the Response Free Survival (RFS) at 6 months following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab. Completed

To retrospectively evaluate outcomes following CAR T-cell therapy across children and young adults with B-ALL

Secondary

To evaluate the RFS at 12 months following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab and other immunotherapy. Completed

To evaluate the incidence of CD19 negative versus CD19 positive relapse following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab. Completed

To evaluate the Complete Response (CR) rate following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab. Completed

To evaluate the Minimal Residual Disease (MRD) negative remission rate following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab. Completed

To evaluate the impact of prior blinatumomab, prior inotuzumab, and other immunotherapies on subsequent CAR T cell outcomes.

To determine the incidence, severity, resolution and risk factors for early and late cytopenias after CAR T-cell therapy.

To evaluate the response of extramedullary disease following CAR T-cell therapy.

To evaluate the frequency of subsequent malignant neoplasms after CAR T-cell therapy.

To describe response, survival, and toxicities after CAR T-cell therapy in children with trisomy 21 and other important subpopulations.

To determine the impact of next-generation sequencing MRD results and duration of B-cell aplasia on CAR T cell outcomes.

To evaluate the frequency of infections and describe immune system function after CAR T-cell therapy.

To describe response, survival, and toxicities after CAR T-cell therapy in children with leukemia containing specific cytogenetic lesions (e.gl. TP53, t(1;19), hypodiploidy).

To compare toxicities and outcomes across CAR T-cell constructs (e.g., different CD19 CAR constructs, dual-targeted CARs, CD22-targeted CARs, etc.).

To assess the impact of CAR T cells on other health-related outcomes, including, but not limited to, organ function, immune reconstitution, quality of life, and patient-reported outcomes.

Study Population and Source of Data: Subjects who were less than < 25 years of age at the time of diagnosis and received a CAR T-cell product for B-ALL.

Panoramica dello studio

Stato

Completato

Condizioni

Descrizione dettagliata

Study Description:

This retrospective protocol focuses on characterizing clinical outcomes and toxicities following CAR T-cell therapy.

Objectives:

Primary

  • To evaluate the Response Free Survival (RFS) at 6 months following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab. COMPLETED.
  • To retrospectively evaluate outcomes following CAR T-cell therapy across children and young adults with B-ALL

Secondary

  • To evaluate the RFS at 12 months following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab and other immunotherapy. COMPLETED.
  • To evaluate the incidence of CD19 negative versus CD19 positive relapse following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab. COMPLETED.
  • To evaluate the Complete Response (CR) rate following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab. COMPLETED.
  • To evaluate the Minimal Residual Disease (MRD) negative remission rate following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab. COMPLETED.
  • To evaluate the impact of prior blinatumomab, prior inotuzumab, and other immunotherapies on subsequent CAR T cell outcomes.
  • To determine the incidence, severity, resolution and risk factors for early and late cytopenias after CAR T-cell therapy.
  • To evaluate the response of extramedullary disease following CAR T-cell therapy.
  • To evaluate the frequency of subsequent malignant neoplasms after CAR T-cell therapy.
  • To describe response, survival, and toxicities after CAR Tcell therapy in children with trisomy 21 and other important subpopulations.
  • To determine the impact of next-generation sequencing MRD results and duration of B-cell aplasia on CAR T cell outcomes.
  • To evaluate the frequency of infections and describe immune system function after CAR T-cell therapy.
  • To describe response, survival, and toxicities after CAR Tcell therapy in children with leukemia containing specific cytogenetic lesions (e.gl. TP53, t(1;19), hypodiploidy).
  • To compare toxicities and outcomes across CAR T-cell constructs (e.g., different CD19 CAR constructs, dual-targeted CARs, CD22-targeted CARs, etc.).
  • To assess the impact of CAR T cells on other health-related outcomes, including, but not limited to, organ function, immune reconstitution, quality of life, and patient-reported outcomes.

Tipo di studio

Osservativo

Iscrizione (Effettivo)

57

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Maryland
      • Bethesda, Maryland, Stati Uniti, 20892
        • National Cancer Institute (NCI)

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 3 anni a 25 anni (Bambino, Adulto)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Metodo di campionamento

Campione di probabilità

Popolazione di studio

Subjects who were less than or equal to 25 years of age at the time of diagnosis and received a CAR T-cell product for B-ALL. This protocol will be amended to incorporate new research objectives and new data as necessary.

Descrizione

  • Subjects will not be recruited for this study; however, up to 210 subjects records will be selected from treatment protocols who received CAR therapy for B-ALL. Subject who opted out of the future use of his/her data will be excluded. The subjects enrolled to a CAR T cell therapy treatment protocol within the Pediatric Oncology Branch unless, are < 25 years of age at the time of diagnosis and must have received prior a CAR T-cell product.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Modelli osservazionali: COHORT
  • Prospettive temporali: RETROSPECTIVE

Coorti e interventi

Gruppo / Coorte
1

Retrospective chart review of children and adults with cancer enrolled on immunotherapy treatment protocols

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Response free survival (completed)
Lasso di tempo: 6 months

To evaluate the RFS at 6 months following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab.

6 months
Outcome evaluation
Lasso di tempo: 12 months

To retrospectively evaluate outcomes following CAR T-cell therapy across children and young adults with B-ALL

12 months

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Complete Response Rate (completed)
Lasso di tempo: 12 months

To evaluate the CR rate following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab

12 months
Relapse Rate (completed)
Lasso di tempo: 12 months

To evaluate the incidence of CD19 negative versus CD19 positive relapse following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab

12 months
Response free survival (completed)
Lasso di tempo: 12 months

To evaluate the RFS at 12 months following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab

12 months
Minimal Residual Disease detection (completed)
Lasso di tempo: 12 months

To evaluate the MRD negative remission rate following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab

12 months
Impact of immunotherapies on CAR outcomes
Lasso di tempo: 12 months

To evaluate the impact of prior blinatumomab, prior inotuzumab, and other immunotherapies on subsequent CAR T cell outcomes

12 months
Cytopenias after CAR
Lasso di tempo: 12 months

To determine the incidence, severity, resolution and risk factors for early and late cytopenias after CAR T cell outcomes

12 months
Response of extramedullary disease
Lasso di tempo: 12 months

To evlauate the response of extramedullary disease following CAR T cell therapy

12 months
Frequency of malignant neoplasms
Lasso di tempo: 12 months

To evaluate the response of extramedullary disease following CAR T cell therapy

12 months
Response, survival and toxicities in subpopulations
Lasso di tempo: 12 months

To describe response, survival, and toxicities after CAR T-cell therapy in children with trisomy 21 and other important subpopulations.

12 months
Impact of next generation sequencing MRD and duration of B cell aplasia
Lasso di tempo: 12 months

To determine the impact of next-generation sequencing MRD results and duration of B-cell aplasia on CAR T cell outcomes.

12 months
Frequency of infections
Lasso di tempo: 12 months

To evaluate the frequency of infections and describe immune system function after CAR T-cell therapy.

12 months
Response, survival and toxicities after CAR
Lasso di tempo: 12 months

To describe response, survival, and toxicities after CAR T-cell therapy in children with leukemia containing specific cytogenetic lesions (e.gl. TP53, t(1;19), hypodiploidy)

12 months
Compare toxicities and outcomes across CAR constructs
Lasso di tempo: 12 months

To compare toxicities and outcomes across CAR T-cell constructs (e.g., different CD19 CAR constructs, dual-targeted CARs, CD22-targeted CARs, etc.)

12 months
Impact of CAR on other health-related outcomes
Lasso di tempo: 12 months

To assess the impact of CAR T cells on other health-related outcomes, including, but not limited to, organ function, immune reconstitution, quality of life, and patient-reported outcomes

12 months

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Investigatore principale: Sara K Silbert, M.D., National Cancer Institute (NCI)

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

14 ottobre 2021

Completamento primario (Effettivo)

29 ottobre 2024

Completamento dello studio (Effettivo)

29 ottobre 2024

Date di iscrizione allo studio

Primo inviato

29 giugno 2022

Primo inviato che soddisfa i criteri di controllo qualità

29 giugno 2022

Primo Inserito (Effettivo)

30 giugno 2022

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

26 ottobre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

23 ottobre 2026

Ultimo verificato

22 ottobre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • 10000651
  • 000651-C

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

All IPD recorded in the medical record will be shared with intramural investigators upon request.

Periodo di condivisione IPD

Clinical data available during the study and indefinitely.

Criteri di accesso alla condivisione IPD

Clinical data will be made available via subscription to BTRIS and with the permission of the study PI.

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO
  • LINFA

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .